Trials / Completed
CompletedNCT03002519
Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Pluristem Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects with incomplete hematopoietic recovery following HCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PLX-R18 | Intramuscular (IM) administration of PLX-R18 |
Timeline
- Start date
- 2017-02-08
- Primary completion
- 2021-09-30
- Completion
- 2021-10-30
- First posted
- 2016-12-23
- Last updated
- 2022-12-16
Locations
10 sites across 2 countries: United States, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03002519. Inclusion in this directory is not an endorsement.